Characterisation of erusiolin - a new peptide hormone [ 1/1/2021 - 12/31/2023 ]

Research Grant

Brief description Obesity and type II diabetes are epidemic diseases in Australia. Gut-derived hormones are key mediators in these diseases, due to their role in regulating appetite and blood glucose levels. Therapeutic modulation of these hormones also provides significant benefits for patients. In this proposal, we will determine the metabolic functions, such as appetite control, for a previously uncharacterised hormone, which is an unexplored therapeutic target for obesity and diabetes.

Funding Amount $547,202

Funding Scheme Ideas Grants

Chief Investigator Dr Mark Larance

Notes Ideas Grants